Published in Leuk Lymphoma on January 01, 2010
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2012) 1.38
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer (2011) 1.19
Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget (2010) 1.00
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica (2014) 1.00
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood (2013) 0.96
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol (2014) 0.93
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood (2014) 0.90
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma (2011) 0.90
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int (2014) 0.86
Lenalidomide and chronic lymphocytic leukemia. Biomed Res Int (2013) 0.81
Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther (2011) 0.79
Lenalidomide in the treatment of chronic lymphocytic leukemia. Adv Hematol (2012) 0.78
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Curr Hematol Malig Rep (2016) 0.77
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J (2016) 0.76
The emerging role of lenalidomide in the management of lymphoid malignancies. Ther Adv Hematol (2011) 0.75
Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter (2016) 0.75
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.75
Food security: the challenge of feeding 9 billion people. Science (2010) 22.51
SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol (2005) 10.04
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Regions of strong coupling between soil moisture and precipitation. Science (2004) 5.96
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell (2009) 5.55
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Left atrial and right ventricular myxoma: an uncommon presentation of a rare tumour. Interact Cardiovasc Thorac Surg (2011) 3.17
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell (2011) 3.12
Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA (2011) 3.03
Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. Br J Psychiatry (2011) 2.17
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
The effect of recalling paracetamol on hospital admissions for poisoning in Western Australia. Med J Aust (2003) 2.11
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res (2003) 2.09
Characterization of long-term outcomes after Toupet fundoplication: symptoms, medication use, and health status. J Clin Gastroenterol (2002) 2.08
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) (2009) 2.06
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol (2007) 2.05
A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med (2008) 1.95
One-third of adult smokers have a mental illness. Aust N Z J Psychiatry (2009) 1.95
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. J Cell Biol (2006) 1.85
Length of survival of patients with cancer in hospice: a retrospective analysis of patients treated at a major cancer center versus other practice settings. J Palliat Med (2007) 1.81
Definitive hematopoietic stem/progenitor cells manifest distinct differentiation output in the zebrafish VDA and PBI. Development (2009) 1.79
Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol (2004) 1.75
Mammalian overlapping genes: the comparative perspective. Genome Res (2004) 1.74
Speech perception for adults who use hearing aids in conjunction with cochlear implants in opposite ears. J Speech Lang Hear Res (2006) 1.74
The future of the global food system. Philos Trans R Soc Lond B Biol Sci (2010) 1.71
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ (2007) 1.66
Measuring patient-centered communication in cancer care: a literature review and the development of a systematic approach. Soc Sci Med (2011) 1.63
Advanced dental disease in people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry (2011) 1.63
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood (2006) 1.63
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 1.59
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol (2008) 1.57
Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One (2011) 1.55
Prevention of child behavior problems through universal implementation of a group behavioral family intervention. Prev Sci (2005) 1.54
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res (2005) 1.53
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr (2006) 1.52
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A (2012) 1.51
Antecedents of hospital admission for deliberate self-harm from a 14-year follow-up study using data-linkage. BMC Psychiatry (2010) 1.50
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1. Leuk Lymphoma (2012) 1.50
Variation of BMP3 contributes to dog breed skull diversity. PLoS Genet (2012) 1.49
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat (2011) 1.46
Is outcomes research on cancer ready for prime time? Med Care (2002) 1.41
Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med (2011) 1.41
Smoke signals. Recognition and treatment of combustion-induced cyanide toxicity. JEMS (2009) 1.39
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev (2009) 1.37
Enhancing measurement in health outcomes research supported by Agencies within the US Department of Health and Human Services. Qual Life Res (2007) 1.37
TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell (2012) 1.34
Mortality in individuals who have had psychiatric treatment: population-based study in Nova Scotia. Br J Psychiatry (2005) 1.34
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest (2013) 1.33
Design and validation of a clinical instrument for spectral diagnosis of cutaneous malignancy. Appl Opt (2010) 1.33
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol (2004) 1.32
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther (2010) 1.30
Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol (2009) 1.30
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
Cancer-related mortality in people with mental illness. JAMA Psychiatry (2013) 1.28
Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction (2002) 1.27
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Indigenous well-being in four countries: an application of the UNDP'S human development index to indigenous peoples in Australia, Canada, New Zealand, and the United States. BMC Int Health Hum Rights (2007) 1.26
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med (2005) 1.25
Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg (2012) 1.23
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest (2006) 1.20
Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw (2013) 1.20
Excess cancer mortality in psychiatric patients. Can J Psychiatry (2008) 1.20
Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res (2013) 1.19
Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.19